AndroGel® (testosterone gel) 1% and 1.62% CIII are indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:
Limitations of use:
Use in specific populations:There are insufficient long-term safety data in geriatric patients using AndroGel to assess the potentially increased risks of cardiovascular disease and prostate cancer.
Please see full Prescribing Information for AndroGel 1% and AndroGel 1.62%.
References: 1. AndroGel 1.62% [package insert]. North Chicago, IL: AbbVie Inc. 2. AndroGel 1% [package insert]. North Chicago, IL: AbbVie Inc.
Copyright © 2015 AbbVie Inc. North Chicago, IL 60064 1882985-1730328 May 2015